1281 related articles for article (PubMed ID: 32503814)
1. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
Andreou A; Trantza S; Filippou D; Sipsas N; Tsiodras S
In Vivo; 2020 Jun; 34(3 Suppl):1567-1588. PubMed ID: 32503814
[TBL] [Abstract][Full Text] [Related]
2. COVID-19: Rescue by transcriptional inhibition.
Shilatifard A
Sci Adv; 2020 Jul; 6(27):. PubMed ID: 32937442
[No Abstract] [Full Text] [Related]
3. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
Sheahan TP; Sims AC; Zhou S; Graham RL; Pruijssers AJ; Agostini ML; Leist SR; Schäfer A; Dinnon KH; Stevens LJ; Chappell JD; Lu X; Hughes TM; George AS; Hill CS; Montgomery SA; Brown AJ; Bluemling GR; Natchus MG; Saindane M; Kolykhalov AA; Painter G; Harcourt J; Tamin A; Thornburg NJ; Swanstrom R; Denison MR; Baric RS
Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32253226
[TBL] [Abstract][Full Text] [Related]
4. Uncertainty about the Efficacy of Remdesivir on COVID-19.
Yoo JH
J Korean Med Sci; 2020 Jun; 35(23):e221. PubMed ID: 32537956
[No Abstract] [Full Text] [Related]
5. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
[TBL] [Abstract][Full Text] [Related]
6. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.
Sun D
AAPS J; 2020 May; 22(4):77. PubMed ID: 32458279
[TBL] [Abstract][Full Text] [Related]
7. Current pharmacological treatments for SARS-COV-2: A narrative review.
Nittari G; Pallotta G; Amenta F; Tayebati SK
Eur J Pharmacol; 2020 Sep; 882():173328. PubMed ID: 32603692
[TBL] [Abstract][Full Text] [Related]
8. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.
Williamson BN; Feldmann F; Schwarz B; Meade-White K; Porter DP; Schulz J; van Doremalen N; Leighton I; Yinda CK; Pérez-Pérez L; Okumura A; Lovaglio J; Hanley PW; Saturday G; Bosio CM; Anzick S; Barbian K; Cihlar T; Martens C; Scott DP; Munster VJ; de Wit E
Nature; 2020 Sep; 585(7824):273-276. PubMed ID: 32516797
[TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
Jockusch S; Tao C; Li X; Chien M; Kumar S; Morozova I; Kalachikov S; Russo JJ; Ju J
Sci Rep; 2020 Oct; 10(1):16577. PubMed ID: 33024223
[TBL] [Abstract][Full Text] [Related]
10. Audio Interview: New Data on Remdesivir in Covid-19.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 May; 382(22):e94. PubMed ID: 32459948
[No Abstract] [Full Text] [Related]
11. Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature.
Musa A; Pendi K; Hashemi A; Warbasse E; Kouyoumjian S; Yousif J; Blodget E; Stevens S; Aly B; Baron DA
West J Emerg Med; 2020 May; 21(4):737-741. PubMed ID: 32726230
[TBL] [Abstract][Full Text] [Related]
12. Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?
Thalha AMM; Lee YY; Besari A; Omar SFS
J R Coll Physicians Edinb; 2020 Jun; 50(2):159-161. PubMed ID: 32568289
[No Abstract] [Full Text] [Related]
13. [Remdesivir, the antiviral hope against SARS-CoV-2].
Reina J
Rev Esp Quimioter; 2020 Jun; 33(3):176-179. PubMed ID: 32239125
[TBL] [Abstract][Full Text] [Related]
14. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
15. Arguments in favour of remdesivir for treating SARS-CoV-2 infections.
Ko WC; Rolain JM; Lee NY; Chen PL; Huang CT; Lee PI; Hsueh PR
Int J Antimicrob Agents; 2020 Apr; 55(4):105933. PubMed ID: 32147516
[No Abstract] [Full Text] [Related]
16. Case report study of the first five COVID-19 patients treated with remdesivir in France.
Dubert M; Visseaux B; Isernia V; Bouadma L; Deconinck L; Patrier J; Wicky PH; Le Pluart D; Kramer L; Rioux C; Le Hingrat Q; Houhou-Fidouh N; Yazdanpanah Y; Ghosn J; Lescure FX
Int J Infect Dis; 2020 Sep; 98():290-293. PubMed ID: 32619764
[TBL] [Abstract][Full Text] [Related]
17. A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir.
Liang C; Tian L; Liu Y; Hui N; Qiao G; Li H; Shi Z; Tang Y; Zhang D; Xie X; Zhao X
Eur J Med Chem; 2020 Sep; 201():112527. PubMed ID: 32563812
[TBL] [Abstract][Full Text] [Related]
18. Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More.
Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
Arch Med Res; 2020 Aug; 51(6):585-586. PubMed ID: 32439198
[TBL] [Abstract][Full Text] [Related]
19. Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?
Carradori S
Antiinflamm Antiallergy Agents Med Chem; 2020; 19(2):85-87. PubMed ID: 32213152
[No Abstract] [Full Text] [Related]
20. Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19.
Jorgensen SCJ; Kebriaei R; Dresser LD
Pharmacotherapy; 2020 Jul; 40(7):659-671. PubMed ID: 32446287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
